1. Abu-Amero K.K., Kondkar A.A., Chalam K.V.: Resveratrol andophthalmic diseases. Nutrients, 2016; 8: 200 2 Agarwal A., Rhoades W.R., Hanout M., Soliman M.K., Sarwar S.,Sadiq M.A., Sepah Y.J., Do D.V., Nguyen Q.D.: Management of neovascularage-related macular degeneration: Current state-of-the-artcare for optimizing visual outcomes and therapies in development.Clin. Ophthalmol., 2015; 9: 1001–1015
2. study: Micronutrients in the treatment of macular degeneration.Adv. Nutr., 2017; 8: 40–53
3. Ardeljan D., Tuo J., Chan C.C.: Carboxyethylpyrrole plasma biomarkersin age-related macular degeneration. Drugs Future, 2011;36: 712–718
4. Bellezza I.: Oxidative stress in age-related macular degeneration:Nrf2 as therapeutic target. Front. Pharmacol., 2018; 9: 1280
5. Bergmann M., Schütt F., Holz F.G., Kopitz J.: Inhibition of theATP-driven proton pump in RPE lysosomes by the major lipofuscinfluorophore A2-E may contribute to the pathogenesis of age-relatedmacular degeneration. FASEB J., 2004; 18: 562–564